NervGen Pharma (NGEN) said late Thursday it elected to voluntarily delist its common shares from the TSX Venture Exchange, effective at the close of markets Monday.

The move is intended to eliminate duplicative exchange fees, reduce legal, accounting and regulatory complexity, and allow greater focus on clinical execution and long-term shareholder value.

NervGen said all shareholders, including those in Canada, will continue to have full trading access to their common shares on Nasdaq.

In connection with the voluntary delisting, the company said it has terminated its at-the-market equity program launched on Dec. 19, 2025.